LTRN Lantern Pharma Inc
Company Analysis
Latest News
🔴 Lantern Pharma is trading 5.18% down today with no clear catalyst identified
Lantern Pharma is trading 5.18% down at $1.83 after falling from the September 2, 2026 close of $1.93; the cause remains unclear despite broader equities and...
🔴 Lantern Pharma is trading 5.69% down today — no clear company-specific catalyst identified
Lantern Pharma is trading 5.69% down at $1.91 after no clear company-specific catalyst was identified for September 2, 2026. - Recent coverage centers on the...
🔴 Lantern Pharma is trading 10.4% down in pre-market; reason unconfirmed
Lantern Pharma is trading 10.4% down at $1.81 in pre-market, with no clear company-specific announcement identified for September 2, 2026; the reason remains...
🟢 Lantern Pharma is trading 5.5% up today as Nasdaq and S&P 500 rise
Lantern Pharma is trading 5.5% up at $2.30 amid a broadly positive August 27, 2026 session. - The Nasdaq Composite is up 1.34%, while the S&P 500 is up 0.59%,...
🔴 Lantern Pharma is trading 8.26% down in pre-market — no specific catalyst identified
Lantern Pharma is trading 8.26% down at $2.00, versus the August 25, 2026 close of $2.18; no specific catalyst was identified. - No new company-specific...
🟢 Lantern Pharma rises 5.5% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
🔴 Lantern Pharma is trading 10.26% down today as no clear catalyst explains decline
Lantern Pharma is trading at $2.10, down 10.26%, with no confirmed catalyst for the August 24 decline. - Weakness extended after the August 21, 2026 close at...
🔴 Lantern Pharma is trading 6.4% down today with no clear company-specific catalyst identified
Lantern Pharma is trading at $2.19, down -6.41%, with no clear company-specific announcement or catalyst identified for August 24, 2026. - Investor sentiment...
🔴 Lantern Pharma is trading 10.26% down in pre-market; no clear company-specific catalyst
Lantern Pharma is trading 10.26% down at $2.10 in pre-market, with no fresh company-specific announcement clearly explaining the decline. - The latest...
🔴 Lantern Pharma falls 5.6% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🟢 Lantern Pharma is trading 12.85% up today in pre-market with XBI up 2.27%
Lantern Pharma is trading 12.85% up at $2.81 amid biotech sentiment, with XBI up 2.27% pre-market amid positive cancer-trial news. - No verified...
🟢 Lantern Pharma is trading 10.43% up in after-hours trading with no verified catalyst
Lantern Pharma is trading 10.43% up at $2.75 in after-hours trading, with no verified company-specific announcement emerging on August 19, 2026. - Latest...
🟢 Lantern Pharma rises 5.2% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🔴 Lantern Pharma is trading 5.7% down in pre-market after Q2 loss miss and funding warning
Lantern Pharma is trading 5.7% down in pre-market at $2.50 as investors continued digesting its August 14 second-quarter earnings release, including a loss...
Lantern Pharma's Cash Clock Is Ticking — Can Promising Trial Data Outrun a Looming Dilution Squeeze?
Shares of Lantern Pharma (LTRN) tumbled 8.7% to $2.40 on August 14 after second-quarter results exposed a widening gap between the company's clinical ambitions...
🔴 Lantern Pharma is trading 8.75% down today after Q2 loss exceeded analyst expectations
Lantern Pharma is trading 8.75% down at $2.40 after its August 14, 2026, second-quarter results showed a $7.1 million net loss, or $0.57 per share, versus...
Lantern Pharma's second quarter operating loss fell 25% as HARMONIC trial data improved
Lantern Pharma reported a second quarter 2026 loss from operations of $3.5 million, reflecting a 25% improvement year-over-year. While net loss widened to $7.1...
Lantern Pharma Inc Q2 2026 Earnings Preview: What Analysts Expect on August 12, 2026
Lantern Pharma is expected to report a Q2 2026 loss of $0.38 per share on $0 revenue, with its current stock price of $2.88 significantly trailing the average...
Lantern Pharma Gets a European Green Light for Its Lead Cancer Drug — But Can a $37 Million Company Afford to Run the Race?
Shares of Lantern Pharma surged 10.3% to $2.90 after Europe's top drug regulator cleared the company to begin a mid-stage human trial of its lead cancer...
🔴 Lantern Pharma is trading 5.7% down today on profit-taking after AI spin-out rally
Lantern Pharma is trading at $2.64 (5.7% down) as investors lock in gains following a multi-day rally tied to the company's AI-related spin-out. • The decline...